176 related articles for article (PubMed ID: 38074953)
21. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study.
Wei J; Zou C; Wang D; Huang A; Niu S
J Glob Antimicrob Resist; 2020 Sep; 22():448-451. PubMed ID: 32387260
[TBL] [Abstract][Full Text] [Related]
22. Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options.
Zhang L; Zhen S; Shen Y; Zhang T; Wang J; Li J; Lin Q; Xiao Z; Zheng Y; Jiang E; Han M; Wang J; Feng S
Ann Clin Microbiol Antimicrob; 2023 May; 22(1):41. PubMed ID: 37202758
[TBL] [Abstract][Full Text] [Related]
23. Ceftazidime-Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients.
Shi Y; Hu J; Liu P; Wang T; Wang H; Liu Y; Cao Q; Zuo X
Infect Dis Ther; 2021 Dec; 10(4):2721-2734. PubMed ID: 34652713
[TBL] [Abstract][Full Text] [Related]
24. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S; Wang H; Feng S
Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
[TBL] [Abstract][Full Text] [Related]
25. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
26. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
[TBL] [Abstract][Full Text] [Related]
27. Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant
Sun S; Chen K; Kong X; Tian W; Niu S
Infect Drug Resist; 2022; 15():2243-2251. PubMed ID: 35510161
[TBL] [Abstract][Full Text] [Related]
28. The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant
Abu Jaber AMR; Basgut B; Hawan AA; Al Shehri AA; AlKahtani SA; Ahmed NJ; Abdi A
Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534700
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
Zhong H; Zhao XY; Zhang ZL; Gu ZC; Zhang C; Gao Y; Cui M
Int J Antimicrob Agents; 2018 Oct; 52(4):443-450. PubMed ID: 30012440
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
Qu J; Xu J; Liu Y; Hu C; Zhong C; Lv X
Int J Antimicrob Agents; 2023 Aug; 62(2):106872. PubMed ID: 37247645
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant
Fang J; Li H; Zhang M; Shi G; Liu M; Wang Y; Bian X
Front Pharmacol; 2021; 12():780940. PubMed ID: 34955849
[No Abstract] [Full Text] [Related]
33. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
[TBL] [Abstract][Full Text] [Related]
34. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
[TBL] [Abstract][Full Text] [Related]
35. Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed
Gupta N; Boodman C; Prayag P; Manesh A; Kumar TP
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):203-209. PubMed ID: 38258529
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.
Hakeam HA; Alsahli H; Albabtain L; Alassaf S; Al Duhailib Z; Althawadi S
Int J Infect Dis; 2021 Aug; 109():1-7. PubMed ID: 34091006
[TBL] [Abstract][Full Text] [Related]
37. Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant
Wang W; Wang R; Zhang Y; Zeng L; Kong H; Bai X; Zhang W; Liang T
Infect Drug Resist; 2022; 15():3323-3332. PubMed ID: 35782529
[TBL] [Abstract][Full Text] [Related]
38. Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study.
Zhuang HH; Qu Q; Long WM; Hu Q; Wu XL; Chen Y; Wan Q; Xu TT; Luo Y; Yuan HY; Lu Q; Qu J
Infection; 2024 Jun; ():. PubMed ID: 38884857
[TBL] [Abstract][Full Text] [Related]
39. Combination Therapy of Ceftazidime/Avibactam for the Treatment of Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae: A Multicenter Retrospective Study.
Lin J; Zhang L; Zhou M; Tian X; Chen J; Lu M; Liu Z
Infect Dis Ther; 2023 Aug; 12(8):2165-2177. PubMed ID: 37653121
[TBL] [Abstract][Full Text] [Related]
40. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
